anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation method of an effervescent tablet containing CS-4 fermented cordyceps sinensis powder, which comprises the following steps: 65 parts of citric acid, 98 parts of lactose, 200 parts of purified water, 50 parts of honey, 125 parts of CS-4 fermented cordyceps sinensis powder, 50 parts of sodium bicarbonate, 30 parts of silicon dioxide and 2 parts of magnesium stearate, and the preparation method comprises the following steps: dissolving citric acid and lactose in purified water, adding Mel and CS-4 fermented Cordyceps powder, stirring, drying, pulverizing, adding sodium bicarbonate, silicon dioxide and magnesium stearate, mixing, and tabletting to obtain effervescent tablet with weight of 0.4g per tablet. 1. Compared with the traditional Jinshuibao tablets, the effervescent tablet (1) has novel dosage form, convenient taking and quick effect; (2) the oral liquid has good taste and good patient compliance, and is particularly suitable for the elderly and patients who have difficulty in swallowing solid preparations; (3) rapidly disintegrating within 1-5 min; (4) the bioavailability is high, and the clinical curative effect can be improved; (5) the medicine is slightly acidic, so that the stability and the solubility of the medicine can be improved; (6) is convenient for carrying, transporting and storing. 2. The stability of the effervescent tablet is improved by introducing the silicon dioxide auxiliary material. 3. The low temperature drying ensures the stability of the wet mixed soft material by using a vacuum belt drying technology.
The mid-range dose of BCG (4x standard Malawi dose (BCG Bulgaria 600000-2400000 cfu intradermal) and equal to the model tested in Oxford, UK) will be used to determine safety and feasibility. The investigators hope to to be able to meet study endpoints (measuring microbiological and immunological features of BCG skin lesion) in this arm which will recruit 10 subjects.
PROBLEM TO BE SOLVED: To provide a means with which a patient can comprehend the described contents of his own medical record without requiring the lavor of any other person such as a doctor. SOLUTION: When the described contents of the medical record can not be comprehended, they are comprehended by getting the explanation of these descriptions through a medical record translation system. In the case of electronic medical record, an ID is inputted from an operating terminal part 1 and the medical record is retrieved from an electronic medical record storage part 14 by a medical record retrieving part 8. In the case of the handwritten medical record, the image of the medical record is read from a scanner part 3, and respective characters are recognized by a character recognizing part 10. The retrieved contents are displayed on a picture display part 5, and the desired section to be translated for the patient is designated by the mouse or the like of the operating terminal part 1. The semantic contents of respective terms included in the designated translation range are retrieved by a term retrieval part 11, the explanatory sentence of terms is constituted by a translation part 12 while using the meaning of terms retrieved by the term retrieving part 11, and displayed on the picture display part 5 by an output processing part 14 and the semantic contents of terms in the medical record are presented for the patient.
Patients assigned to this arm will receive SBRT alone. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
It has been previously reported that 2:1 AVB in neonatal LQTS seems preferentially associated with HERG mutations . It has also been reported in association with the SCN5A gene. We report on a neonate with congenital LQTS and congenital complete heart block who experienced frequent episodes of torades des pointe and ventricular tachycardia, which, over the first 2 days of life, was recalcitrant to traditional therapy of beta-blockers and other antiarrhythmics. Eventually hypotension necessitated the use of an epinephrine infusion, which halted the ventricular tachyarrhythmias. A pacemaker was implanted once the infant was stable and, currently, he is thriving. Genetic analysis revealed a HERG mutation.

For this study, we will need access to the infant's inpatient and outpatient medical records at Children's Healthcare of Atlanta at Egleston Children's Hospital and Sibley Heart Center Cardiology to include his age, date of birth, medical record number, inpatient labs, inpatient echo reports, outpatient echo reports, inpatient and outpatient EKG's, inpatient pharmacy records, the results of his genetic analysis, his history and physical, transfer notes, daily progress notes, consultation reports and operative reports from his admission beginning 9/30/04.
Patients in this treatment group will receive placebo respective. Continuous administration for 7 days.
PURPOSE: To obtain a flavor which contains a flavor component firmly bonded to a substance which sticks on a living body and to obtain a flavor which sticks to a wet region in a mouth, can dissolve and release the flavor component at a desired time and gives specific feeling in a mouth. CONSTITUTION: This flavor is obtd. by spray drying a flavor such as spearmint oil and cinnamon oil, a substance such as amylopectin and carboxymethyl cellulose which sticks to a living body, an aminoacid-based sweetener, and a purifying agent such as α-ionone for breath, with a hydrophobic material such as fat and wax and a diluent. For example, a spray dried flavor component comprising a flavor component, hydrophilic compd. and sweetener is mixed with the obtd. flavor and compressed to obtain compressed sweet tablets. The tablets contain 0.05 to 0.35wt.% flavor, 500ppm sweetener and 0.5 to 30wt.% substance which sticks to a living body.
Dexmethylphenidate hydrochloride extended-release capsules are for oral administration once daily in the morning.

Dexmethylphenidate hydrochloride extended-release capsules may be swallowed as whole capsules or alternatively may be administered by sprinkling the capsule contents on a small amount of applesauce (see specific instructions below). Dexmethylphenidate hydrochloride extended-release capsules and/or their contents should not be crushed, chewed, or divided.

The capsules may be carefully opened and the beads sprinkled over a spoonful of applesauce. The mixture of drug and applesauce should be consumed immediately in its entirety. The drug and applesauce mixture should not be stored for future use.

Dosage should be individualized according to the needs and responses of the patient.
This is a prospective, multi-centre, phase IV, biomarker-strategy design trial with a randomised control group in which adult liver transplant recipients will undergo immunosuppression (IS) withdrawal. Immunosuppression drugs (IS) are: Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine.

Enrolled participants will be randomised 1:1 to either: 1) Non-Biomarker-based IS weaning (Weaning-All; Arm A); or 2) Biomarker-based IS weaning (Arm B). In participants allocated to Arm A IS will be withdrawn regardless of the result of the biomarker test. Among participants allocated to Arm B, only those found to be biomarker-positive (Arm B+, i.e. potentially tolerant) will be offered IS withdrawal, while biomarker-negative participants (Arm B-, i.e. potentially non-tolerant) will remain on their baseline maintenance IS. This will allow us to demonstrate that the biomarker is a useful test to personalise IS by offering drug withdrawal only to those participants who are likely to complete the process successfully, avoiding unnecessary rejections among those who have not developed tolerance. Comparing the outcome of IS withdrawal between arms A and B+ will provide direct evidence of the clinical usefulness of the test as a function of its predictive accuracy. We have established that for the biomarker to drive safe IS withdrawal its Positive Predictive Value should be no less than 0.80, and its sensitivity at least 070. To account for centre effects, we will use stratified randomization. Furthermore, to avoid biases, participants undergoing drug withdrawal and their physicians will be blinded to the biomarker results. Participants randomized to Arm B- will know their biomarker status, and will be maintained in the study until its termination and contribute to secondary clinical outcomes and to the evaluation of the stability of the tolerance signature.

Cost and quality of life (HrQOL) assessments will be conducted alongside the trial to estimate the health-economic implications of the 2 different strategies. Furthermore, sequential biological specimens will be collected to conduct ancillary mechanistic studies. Recruitment will take place in 11 European liver transplant units (King's College Hospital, Royal Free London, Newcastle, Birmingham, Leeds, Edinburgh, Cambridge, Leuven, Hannover, Berlin and Barcelona).
PROBLEM TO BE SOLVED: To obtain an antifungal agent which contains trichomycin and/or pyrrolnitrin, has excellent antifungal activity against fungi in Malassezia and can be used in the medical field. SOLUTION: This antifungal agent contains trichomycin and/or pyrrolnitrin by 0.01-50wt.%, preferably 0.01-10wt.%. Trichomycin is a known substance obtained by culturing Streptomyces hachijoensis, while pyrrolnitrin is a known substance represented by the formula. In addition, a variety of bases, carriers and additives are properly formulated to these ingredients to prepare solution, aerosol, gel, cream, powder, ointment, vaginal suppository. The dose of these active ingredients in this antifungal agent is 1-500mg/kg/day. This agent manifests excellent antifungal activity on Malassezia furfur, a causative microorganism of pityriasis versicolor.
The present invention relates to novel bacteria inhibiting halitosis or oral malodor. In particular, the present invention relates to novel lactic acid bacteria belonging to the genus  Weissella , which can inhibit the proliferation of anaerobic bacteria producing volatile sulfur compounds by interacting with them and generating hydrogen peroxide under aerobic and anaerobic conditions. These lactic acid bacteria of the present invention are isolated from lactic acid bacteria naturally existing in the oral cavity of a person, and identified and deposited as  Weissella cibaria  CMU (Accession No.: KCTC 10650BP),  Weissella cibaria  CMS-1 (Accession No.: KCTC 10678BP),  Weissella cibaria  CMS-2 (Accession No.: KCTC 10679BP) and  Weissella cibaria  CMS-3 (Accession No.: KCTC 10680BP), respectively. The present invention provides the lactic acid bacteria and foods comprising the same for effectively inhibiting the proliferation of halitosis-inducing anaerobic bacteria without corrosion at teeth by using these  Weissella cibaria  lactic acid bacteria strains.
The present invention provides a traditional Chinese preparation for treating the deficiency of qi and blood and a preparation method thereof, which belongs to the technical field of traditional Chinese medicines. The preparation is composed of the following components according to the proportion by weight: 1 to 5 shares of pilose asiabell root, 1 to 5 shares of astragalus root, 1 to 4 shares of white atractylodes rhizome, 1 to 4 shares of nutgrass galingale rhizome, 0.5 to 2 shares of hemlock parsley, 1 to 4 shares of corydalis tuber, 1 to 4 shares of curcuma root, 1 to 5 shares of suberect spatholobus, 1 to 5 shares of angelica, 1 to 4 shares of white peony roots, 1 to 5 shares of barbary wolfberry fruit, 1 to 4 shares of lily bulb, 1 to 4 shares of medicated leaf, 0.5 to 2 shares of cassia twig, 1 to 4 shares of polygala root, 1 to 5 shares of prepared rehmannia root, 1 to 4 shares of licorice root and 1 to 4 shares of Chinese arborvitae kernel, wherein the Chinese herbal medicines are selected, processed and proportioned and are processed by a traditional processing technology. The prepared preparation can be medical powder, pills, capsules or decoction. Compared with the prior art, the preparation has the advantages of scientific and reasonable formula, simple preparation process, convenient administration, etc. The preparation is widely used for preventing and treating myocardial ischemia, choking sensation in the chest, shortness of breath, insufficiency of blood supply of the brain, arterial sclerosis, palmus, limb myasthenia, myasthenia of the whole body, dizziness, etc. Thus, the preparation has an effect of treating diseases if a person suffers from the diseases, and has the effect of building the body if the diseases do not exist. The effective rate of the preparation is 100% through clinical observation.
FIELD: chemistry.SUBSTANCE: present invention relates to a novel product as an additive to a detergent obtained by a) by alkoxylation of a 1,2-dialcohol of formula (III) with alkylene oxides, where the molar ratio of 1,2-dialcohol of formula (III) to alkylene oxides is from 1:3 to 1:4,(III), where one of Rand Rrepresents a linear or branched alkyl group with 3–16 carbon atoms, and the other from Rand Ris hydrogen, and b) aminating the alkoxylated 1,2-dialcohol with ammonia, where the alkylene oxides are selected from the group consisting of propylene oxide, butylene oxide or a mixture thereof. Invention also relates to a process for the preparation of a novel mixture of etheramines, comprising the following steps a) alkoxylation of 1,2-dialcohol of formula (III) with alkylene oxides, where the molar ratio of the 1,2-dialcohol of formula (III) to alkylene oxides is in the range from 1:3 to 1:4,(III), where Rand Rhas the above values, and b) amination of the alkoxylated 1,2-dialcohol with ammonia, wherein the alkylene oxides are selected from the group consisting of propylene oxide, butylene oxide or a mixture thereof. Mainly, propylene oxide is used as alkylene oxide, and 1,2-dialcohol of formula (III) is selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol and 1,2-dodecanediol, 1,2-tetradecanediol, 1,2-hexadecanediol and 1,2-octadecanediol. Amination is carried out in the presence of a copper, nickel or cobalt containing catalyst. Catalytically active substance of catalysts, before its reduction with hydrogen, contains oxygen compounds of aluminium, copper, nickel and cobalt, and in the range from 0.2 to 5.0 wt. % oxygen compounds of tin, calculated as SnO.EFFECT: product obtained by this method, as well as the resulting mixture of ethers, can significantly improve the effectiveness of the detergent at low temperatures of up to 30 °C or even lower when removing fat stains, such as beef tallow, lard, bacon tallow, on cotton products.6 cl, 7 tbl, 5 ex
A quasi-experimental, pre-posttest, two group, study was carried out in NICU of in Smouha, Alexandria. A sample of 62 mechanically ventilated neonates were randomly assigned to two equal groups; the study group wrapped with a warm MSSH during the invasive procedures while the control group received standard care of NICU. Two observers independently rated the neonates' level of comfort, distress, and pain during Endotracheal Suctioning (ETS) and heel prick using COMFORTneo Scale.

On day one of mechanical ventilation, the neonates received the same standard care of the NICU, while they wrapped with a warm Mother-Scented Simulated Hand as follow; simulated hand was scented with mothers' body odor by placing it on the mothers' bare chest or behind the neck for one hour. Then, the MSSH was placed under a radiant warmer for a couple of minutes to reach the mothers' unique warm touch. Inside the incubator, the mechanically ventilated neonates were placed in a side-lying flexed fetal position, where they encircled with the two warm simulated human hand to contain them. Where the palm of one MSSH cupped the neonates' head, and the palm of the other hand cupped the lower part of body and extremities. The neonates were kept in such a position throughout the mentioned invasive procedures. Neonates' physiological response, comfort, distress, and pain levels were assessed the same way as the first day.
Sun tan compsn. contains a mixt. of coco oil (I), bergamot essence (II) and red tea (III) and has different doses of bronzing agent where ratio (II):(I) is increased during successive exposures to sun. The composition is adapted to a progressive browning of the skin in successive exposures up to the 7th day when it has max. conc. of active material.
Background The unique characteristic of community-health care in Thailand is a system of primary- health care officers and Village Health Volunteers (VHVs) providing basic health care to more than 90% of Thai population. Should these allied personnel be trained on how to render proper chronic kidney disease (CKD) care, it would be interesting to study whether their role play care will result in better quality of CKD care.

Design This study is a community-based cluster randomized controlled trial to be conducted in 2 districts of Kamphaeng Phet Province, located about 400 kilometers north of Bangkok. About 300 stage 3-4 CKD patients will be enrolled to each of the 2 treatment groups. Patients in both groups will be treated according to The National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines. The District 1 (control group) patients will be provided a conventional CKD care. For the District 2 (intervention group) patients, an integrated CKD care program will be provided by the multidisciplinary team of district hospital in conjunction with the community CKD care networks (i.e. primary-health care officers and VHVs). The key activities of integrated CKD care program are live demonstration about treatment and optimal diets for CKD patients which will be provided during each hospital visit and quarterly home visits. Clinical and laboratory parameters of all cases will be assessed every 3 months. Duration of the study is 24 months. The primary outcome of this study is the rate of eGFR decline. The secondary outcomes are time of initiation of dialysis, cardiovascular mortality, and all-cause mortality.
Sound and Vision will pair local artists with patients who have had hallucinations to create art pieces that represent their hallucinatory experiences. Patients with diagnoses of schizophrenia and Parkinson's disease will be invited to take part in participating National Health Service (NHS) clinics, to capture and compare a wide range of hallucinatory experiences. Patients will meet with artists on several occasions who will then develop the piece, which may be a painting, drawing, or other media that the artist and service-user jointly select.

Completed artworks will be the centrepiece for an exhibition at United Kingdom (UK) science festivals and a digital (on-line) presentation. The exhibition will be accompanied by researchers explaining the brain science of hallucinations, recordings of patients and artists describing their experience with hallucinations and the process of developing the artworks, booklets cataloguing the exhibition, and art materials available for artistic expression of their own experiences. A digital compendium of the artworks and supporting material will be publicly available alongside the opportunity to complete an online survey exploring the themes of the artworks and collecting information on personal experiences. The objectives are to engage the public in an appreciation of the experience of hallucinations and their prevalence across many common mental health and neurodegenerative disorders, as well as an experience many people will share without ever being diagnosed. The exhibition will also encourage the public to share their own experiences through the online questionnaires creating a platform to begin to improve the understanding of the diversity of hallucination-like experiences in the general population.
Participants will receive a range of doses of AG-181 or placebo, orally, once on Day 1. AG-181 will be given under fasted conditions.
OBJECTIVE: The authors perform thorough, noninvasive presurgical evaluations for intractable epilepsy at their center and avoid unnecessary intracranial EEG when possible. The purpose of this study was to clarify the appropriateness of their lesion-oriented surgical strategy for localized focal cortical dysplasia (FCD) type II.
METHODS: Fifty-one patients with pathologically proven localized FCD type II who were followed for at least 1 year after surgery were included. Patients with FCD type II with lobar or multilobar distribution were excluded. The results of presurgical evaluations, including thin-slice 3-T MRI, FDG-PET, and ictal SPECT, as well as surgical procedures and postoperative seizure and functional outcomes, were examined retrospectively.
RESULTS: MRI was positive in 46 (90%) of 51 patients, and FDG-PET revealed localized hypo- or hypermetabolism in 47 (92%) of 51 patients. Ictal SPECT revealed concordant hyperperfusion in 37 of 42 patients examined. Intracranial EEG was used in only 13 patients (25%), including 5 with negative MRI results and 4 with subtle MRI findings. Of the 15 patients with FCD in the vicinity of eloquent (sensorimotor and language) areas, intracranial EEG was used in 4. Lesionectomy was performed in all 51 patients. Intraoperative electrocorticography (ECoG) was performed in 8 patients, but the findings were not used to tailor the extent of resection. Postoperative seizure outcomes were Engel class I in 47 patients (92%) and Ia in 45 (88%). In the 15 patients with FCD in the vicinity of eloquent areas, 13 (87%) achieved a class I outcome. Predictive factors for favorable seizure outcome were complete resection of the MRI lesion (p = 0.006) and frontal lobe surgery (p = 0.012). Postoperative neurological deficits were noted in only 4 (27%) of 15 patients with FCD in the vicinity of eloquent areas. All 5 MRI-negative patients achieved an Engel class I outcome.
CONCLUSIONS: In most of the patients with localized FCD type II, MRI and/or FDG-PET detected the localized abnormality. Lesionectomy without intracranial EEG led to seizure freedom in most cases. Even when lesions were in the vicinity of eloquent areas, seizure and functional outcomes were favorable. Intraoperative ECoG may thus be unnecessary. Complete resection of the lesion is essential for favorable seizure outcome in MRI-positive patients. In MRI-negative patients, surgery with intracranial EEG guided by FDG-PET provided seizure-free outcomes.
The invention discloses an anti-aging secretory Klotho protein, and a coding gene, a recombinant expression vector and application thereof. The invention adopts gene engineering technology and strategy, optimizes the codon sequence of a target gene by adopting high-fidelity Taq polymerase, adds a histidine tag, and screens to obtain the recombinant anti-aging protein expressed by a prokaryotic expression vector, wherein the amino acid sequence of the recombinant anti-aging protein is shown in SEQ ID NO. 1. The invention also provides a gene for coding the anti-aging secretory Klotho protein, and the sequence of the gene is shown in SEQ ID NO. 2. The Klotho protein obtained in the invention has good anti-aging function, and can be used for anti-aging, regulation of generation of nitric oxide, oxidation stress resistance, regulation of calcium and phosphorus metabolism, anti-inflammation, cancer inhibition and the like.
The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
The effect of hepatic impairment on finasteride pharmacokinetics has not been studied. However, finasteride is extensively metabolized in the liver. Exercise caution in the administration of ENTADFI in those patients with mild to moderate hepatic impairment (Child Pugh Class A or B). Insufficient tadalafil data are available for patients with severe hepatic impairment (Child Pugh Class C). Therefore, ENTADFI use is not recommended in these patients. [see Clinical Pharmacology (12.3)].